Logo image
Back
Thalidomide for the Treatment of Esophageal Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection
Journal article   Open access   Peer reviewed

Thalidomide for the Treatment of Esophageal Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection

Jeffrey M Jacobson, John Spritzler, Lawrence Fox, John L Fahey, J. Brooks Jackson, Miriam Chernoff, David A Wohl, Albert W Wu, Thomas M Hooton, Beverly E Sha, …
The Journal of infectious diseases, Vol.180(1), pp.61-67
07/1999
DOI: 10.1086/314834
PMID: 10353862
url
https://doi.org/10.1086/314834View
Published (Version of record) Open Access

Abstract

A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV). Twenty-four HIV-infected patients with biopsy-confirmed aphthous ulceration of the esophagus were randomly assigned to receive either oral thalidomide, 200 mg/day, or oral placebo daily for 4 weeks. Eight (73%) of 11 patients randomized to receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, compared with 3 (23%) of 13 placebo-randomized patients (odds ratio, 13.82; 95% confidence interval, 1.16-823.75; P=.033). Odynophagia and impaired eating ability caused by esophageal aphthae were improved markedly by thalidomide treatment. Adverse events among patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripheral sensory neuropathy (3 patients). Thalidomide is effective in healing aphthous ulceration of the esophagus in patients infected with HIV.

Details

Metrics

18 Record Views
66 Times Cited - Web of Science
Logo image